WHO clears Oxford and Moderna Bundibugyo vaccines for DRC Ebola trial as deaths pass 5,100

The Democratic Republic of the Congo declared its 17th and largest Ebola outbreak in mid May 2026, and the pathogen driving it is not the Zaire ebolavirus around which most of the world's countermeasures were built. It is Bundibugyo virus, a distinct ebolavirus species for which no vaccine and no specific treatment has been licensed. Al Jazeera reported on November 3, 2026 that the outbreak had killed more than 5,300 people, citing Africa CDC data that put the toll at 5,376 deaths from about 10,444 infections across the DRC, Kenya and Uganda, a case fatality rate above 50 percent.

The response has been an exercise in improvisation under pressure. The only vaccine deployed so far inside the DRC's Tumaini clinical trial is Ervebo, the licensed Zaire ebolavirus vaccine, which is being evaluated against a virus it was not designed to target. Antibody cocktails developed against Zaire Ebola are in the same position. Until this week, no candidate built specifically to protect against Bundibugyo virus had been tested during an active outbreak of that strain.

Tumaini uses a ring vaccination design that enrolls contacts of confirmed cases, an approach pioneered in Guinea during the West Africa Ebola outbreak. Four vaccination rings were already in place before the new candidates were cleared for inclusion. The design lets evaluators compare infection rates in vaccinated and unvaccinated rings under outbreak conditions, rather than relying on a conventional randomised trial that would be slower and ethically harder to run in the middle of an emergency.

The geography of the outbreak explains why speed matters. The European Centre for Disease Prevention and Control reported on November 3, 2026 that the DRC had recorded 10,532 confirmed cases including 5,126 deaths as of November 1, spread across 67 of the country's 178 health zones in eight provinces. Ituri alone accounted for 7,431 cases and 3,492 deaths from 28 of its 36 health zones, followed by Nord-Kivu with 2,518 cases and 1,395 deaths and Haut-Uélé with 467 cases and 205 deaths.

Key Facts

On November 4, 2026, WHO announced from Geneva that expert groups it convened had recommended adding two new Ebola vaccine candidates to the Tumaini trial. The candidates are ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469. According to the agency, the recommendation marks the first time vaccines designed specifically to protect against Bundibugyo virus will be evaluated during an outbreak of the disease.

The recommendation came from WHO's independent Technical Advisory Group on Candidate Vaccine Prioritization. Its meeting report, published on November 4 and running five pages under reference number B09970, summarises deliberations held on September 1, October 19, October 22 and November 2, 2026, all focused on candidates for the Bundibugyo outbreak. For each product the group examined safety data by vaccine platform, preclinical toxicology studies, challenge studies in ferrets and non-human primates, interim phase 1 safety and immunogenicity results, and manufacturing and dose availability. The report records a unanimous recommendation to include both ChAdOx1 BDBV and mRNA-1469 in the phase 2/3 trial in the DRC.

WHO reported on November 4, 2026 that the companies were informed on Monday, November 2, and that the vaccines will enter the trial once national approvals are granted. Director-General Dr Tedros Adhanom Ghebreyesus framed the decision carefully, saying the vaccines 'could become a powerful new tool for bringing it under control' while adding that 'vaccines alone will not end this outbreak.'

The trial is a consortium effort. The DRC's Institut National de Recherche Biomédicale leads it with the University of Antwerp, WHO, Epicentre, Médecins Sans Frontières, the Institute of Tropical Medicine of Antwerp, Africa CDC, the DRC Ministry of Health and the Institut National de Santé Publique, with funding from the Coalition for Epidemic Preparedness Innovations.

The outbreak numbers keep climbing while the science proceeds. CIDRAP reported on November 5, 2026 that the US Centers for Disease Control and Prevention put the multi country total at 10,699 cases and 5,202 deaths. The ECDC assessment recorded 961 patients hospitalised in isolation and 2,834 people who had tested positive and recovered, with 84 percent of identified contacts under follow-up in affected provinces. In the 24 hours to November 1, 65 new confirmed cases and 23 new deaths were reported in Nord-Kivu, Ituri and Haut-Uélé, and 258 new confirmed cases and 134 new deaths had been logged nationally since the agency's previous update on October 30.

Analysis

The decision is best read as a bet on platform diversity rather than on any single product. ChAdOx1 and mRNA-1469 come from different vaccine platforms, and the advisory group explicitly reviewed safety data by platform for each. Testing both inside one ring vaccination trial means the world will learn not only whether a Bundibugyo specific immunogen works, but which platform can be manufactured, shipped and deployed fast enough to matter in a rural outbreak setting.

What this really means is that the bottleneck has moved. For months the binding constraint was that no strain specific candidate existed at all. Now the constraint is approval speed, dose supply and the operational capacity to run rings in provinces where 67 of 178 health zones are affected and where 84 percent of contacts are under follow-up. A vaccine that is recommended but not yet approved, or approved but not yet in vials at the right temperature in the affected health zones, changes nothing on the ground.

The ring design carries its own judgement call. It is fast and ethically defensible because it targets the people at highest risk, and it was proven in Guinea, but it produces evidence that is messier than a randomised controlled trial. Investigators will be comparing rings rather than individuals, and they will be doing so while the epidemic curve moves underneath them. That is a reasonable trade in an outbreak with a case fatality rate above 50 percent, but it means the early 2027 readout should be treated as a strong signal rather than a final verdict.

The bigger picture here is that Bundibugyo has exposed how thin the countermeasure pipeline is outside Zaire ebolavirus. Ervebo and the Zaire specific antibody cocktails were never going to be a complete answer, and the fact that strain specific candidates only reached a trial some six months after the DRC declared the outbreak is the real finding. The system worked, but it worked slowly, and it worked because a trial infrastructure already existed to plug the candidates into.

Why It Matters

The stakes are measured in the daily revisions to the case line. Since its previous assessment on October 30, the ECDC recorded 258 new confirmed cases and 134 new deaths nationally, and an October 31 situation report added 314 deaths to cumulative totals as DRC data were reviewed and harmonised. Those revisions are a reminder that even the baseline numbers are still moving, which strengthens the case for a vaccine that can reach contacts within days of a confirmed diagnosis rather than months.

Cross border spread has already happened. The ECDC documented one case in Nigeria, a woman with travel history to Uganda who developed symptoms on October 7 and tested positive on October 20, later medically evacuated to Switzerland and treated at Geneva University Hospital, with 62 contacts followed. Kenya recorded nine confirmed cases including two deaths as of October 26, all linked to a single imported case. CIDRAP reported on November 5, 2026 that a British healthcare worker was being repatriated for treatment after testing positive in the DRC epicentre and was in stable condition, according to The Guardian. Kenya had released Ebola patients after negative tests, with 52 contacts remaining in quarantine and no new cases since October 19.

For EU and EEA residents, the ECDC assessed the risk as very low. That assessment is reassuring but narrow. The broader importance of the Tumaini expansion is that it creates a repeatable sequence: identify the outbreak strain, convene the advisory group, review preclinical and phase 1 data, and push candidates into an existing ring trial under national approval. If that sequence can be compressed, the next Bundibugyo outbreak, or the next novel ebolavirus, starts from a different baseline.

Next Up

Vaccine results from Tumaini are expected in early 2027, according to WHO, while initial findings from the treatment side are expected in the coming months. The WHO sponsored PARTNERS trial, launched in July, is testing the monoclonal antibody MBP134, the antiviral remdesivir, or both, to improve survival. Maftivimab will soon be added, and a post exposure prophylaxis study with obeldevisir is already under way.

The immediate test is administrative. Both candidates enter the trial only after national approvals in the DRC, and the pace of that process will determine whether the November 4 recommendation turns into vaccinated rings before the outbreak peaks. WHO's own framing leaves the conclusion open: vaccines alone will not end this outbreak, but they could become a powerful new tool for bringing it under control. The coming weeks will show how fast that tool reaches the health zones that need it.